Case Report
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Apr 7, 2005; 11(13): 2041-2044
Published online Apr 7, 2005. doi: 10.3748/wjg.v11.i13.2041
Figure 1
Figure 1 Abdominal CT scan obtained before initiation of SR-LAN therapy (A) showing the liver metastasis (black arrow) at the VI hepatic segment (diameter 70×60 mm). CT scan obtained after 3 (B), 6 (C) and 18 (D) mo of SR-LAN demonstrates a significant reduction in the size of liver metastasis.
Figure 2
Figure 2 Most metastatic tumor cells in the liver demonstrate immunoreactivity for STTR1 (A), STTR2 (B), STTR3 (C), and STTR5 (D) on the cell membrane (×200).
Figure 3
Figure 3 Liver metastasis (black arrow) visualized by whole body scanning with In-111 octreotide (octreoscan) before initiation of SR-LAN therapy (A). Octreoscan obtained after 12 mo of SR-LAN demonstrates a marked reduction in the liver uptake (B).